Intestinal microbiota and mucosal immune system (Gut-Immune Axis)

The intestinal microbiota and mucosal immune system represent a complex, symbiotic ecosystem where trillions of microorganisms interact with the host's gut-associated lymphoid tissue (GALT) to maintain physiological homeostasis (Belkaid & Hand, 2014, Science). This interaction is fundamental for the development of the immune system, the maintenance of the intestinal barrier, and the regulation of systemic inflammatory responses (Round & Mazmanian, 2009, Nature Reviews Immunology). Microbial metabolites, such as short-chain fatty acids (SCFAs), act as signaling molecules that induce the differentiation of regulatory T cells, thereby preventing aberrant immune reactions against commensal bacteria (Wu & Wu, 2012, Journal of Biomedical Science). Disruptions in this balance, known as dysbiosis, are implicated in a wide range of conditions, including inflammatory bowel disease (IBD), obesity, and autoimmune disorders (Khoruts & Sadowsky, 2016, Gastroenterology). Current therapeutic strategies focus on modulating this axis through probiotics, prebiotics, and fecal microbiota transplantation to restore a healthy microbial composition and improve clinical outcomes (Lynch & Pedersen, 2016, New England Journal of Medicine).

Other names

Gut microbiome-immune axisIntestinal microbiome-mucosal immunityGALT-microbiota interactionGut-associated lymphoid tissue-microbiota axis

Interventions targeting this system work by modulating microbial diversity, producing beneficial metabolites like short-chain fatty acids (SCFAs), inducing regulatory T cells (Tregs), and strengthening the intestinal epithelial barrier to prevent translocation of pro-inflammatory factors (Belkaid & Hand, 2014, Science; Round & Mazmanian, 2009, Nature Reviews Immunology).